ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 2686

Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells

David Fox1, Laura Cooney2, Lia Stelzig3, Robert Lafyatis4, Johann Gudjonsson5, Lam Tsoi6, Maureen Mayes7, Ankoor Shah8, Suzanne Kafaja9, William Barry3, Ellen Goldmuntz10, Dawn Smilek11 and Dinesh Khanna6, 1University of Michigan, Dexter, MI, 2University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 3Rho, Durham, NC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Dermatology, University of Michigan, Ann Arbor, MI, 6University of Michigan, Ann Arbor, MI, 7UTHealth Houston Division of Rheumatology, Houston, TX, 8Duke University, Durham, NC, 9Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 10Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, 11Immune Tolerance Network, UCSF, San Francisco, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Fibrosing syndromes, Gene Expression, immunology, Randomized Trial, Systemic sclerosis

Session Information

Date: Tuesday, November 19, 2024

Title: Abstracts: Systemic Sclerosis & Related Disorders – Clinical III

Session Type: Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30 with a pro-fibrotic Th2 phenotype and elevated soluble CD30 observed in autoimmune diseases, including SSc, provide rationale for targeting CD30 as a treatment for SSc.

Methods: The BRAVOS trial was a phase 1/2 multicenter randomized double blinded dose escalation safety study of brentuximab vedotin (BV) in diffuse cutaneous SSc (dcSSc). Three ascending dose cohorts of 8 subjects randomized 6:2 BV vs placebo (PBO) were planned, with doses of 0.6 mg/kg, 1.2 mg/kg, and 1.8 mg/kg (FDA approved dose for HL) administered intravenously every three weeks for 8 doses. Subjects were followed for 48 weeks. Approval by a safety committee was required to proceed to the next higher dose. Due to enrollment challenges, enrollment was closed prior to completing cohort 2. Immunophenotyping of peripheral blood mononuclear cells (PBMCs), histological and immunofluorescent staining of skin biopsies, and bulk RNAseq of skin biopsies were conducted. The primary endpoint was proportion of subjects who experienced at least one Grade 3 or higher adverse event (AE) by the CTACE v5.0 by week 48. Exploratory endpoints included the Modified Rodnan Skin Score (mRSS).

Results: Seventeen subjects with dcSSc were recruited at 5 centers; 8 to cohort 1 and 9 to cohort 2. Mean mRSS at baseline was 28.2 (SD 8.9) and mean disease duration after onset of non-Raynaud’s symptoms was 26.6 months (SD 17.35). Background therapy was mycophenolate in 14/17 and methotrexate in 3/17 subjects. In the BV group, 6 Grade 3 and 1 Grade 4 AEs occurred in 6 subjects, compared to no Grade 3 or higher AEs in the PBO group (Table 1). In a dose response analysis, BV was associated with a greater percent change in mRSS compared to PBO at week 48, however the results were confounded by an imbalance in disease severity at baseline (Table 2).  

Analysis of PBMCs demonstrated a substantial decline in the frequency of CD30+ T and B lymphocyte subsets in blood following BV treatment, which largely returned to baseline by week 48. At week 24 cumulative depletion of several lymphocyte subsets, particularly activated B cells, exceeded what was expected based on the small percentage of CD30+ cells in these subsets at baseline.

Analyses of skin biopsies demonstrated a trend towards a dose-dependent decline in myofibroblasts, identified by alpha smooth muscle actin staining, in BV versus PBO subjects (Figure 1). Bulk skin RNAseq also showed a decline in gene expression of several disease-relevant pathways in the 1.2mg/kg dosing cohort at week 24, including epidermal cell differentiation, regulation of ERK1/2 cascade, and regulation of inflammatory response.

Conclusion: Grade 3 or higher AEs occurred only in the BV group and were consistent with the known safety profile of BV. Although the results were limited by a small sample size, the data suggest improvement in mRSS with BV and show reduced frequencies of several activated lymphocyte populations in the circulation with a trend towards reduced inflammation and pro-fibrotic signals in skin. The results support conducting a larger study to evaluate efficacy of BV in dcSSc.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: D. Fox: Abcon, 8, 10, 11; L. Cooney: None; L. Stelzig: None; R. Lafyatis: AbbVie/Abbott, 1, Bain Capital, 2, Bristol-Myers Squibb(BMS), 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Mediar, 2, Merck/MSD, 1, Modumac Therapeutics inc, 4, Pfizer, 5, Third Rock Venture, 2, Thirona Bio, 2, 11; J. Gudjonsson: AbbVie, 1, 5, Almirall, 1, 5, Boehringer Ingelheim, 1, Eli Lilly, 1, 5, Janssen, 1, 5, Merck, 1, 5, Novartis, 1, Oruka, 1, Renovare Sclerobio, 1, Renovare Therapeutics, 1, Zura Bio, 1; L. Tsoi: Janssen, 5; M. Mayes: AstraZeneca, 5, Atyr, 5, Boehringer-Ingelheim, 1, 5, Horizon Therapeutics, 5, Merck/MSD, 5; A. Shah: Amgen, 5, Boehringer-Ingelheim, 5; S. Kafaja: None; W. Barry: None; E. Goldmuntz: None; D. Smilek: None; D. Khanna: AbbVie/Abbott, 2, Amgen, 2, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Certa Therapeutics, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, MDI Therapeutics, 8, Merck/MSD, 2, Novartis, 2, Zura Bio, 2.

To cite this abstract in AMA style:

Fox D, Cooney L, Stelzig L, Lafyatis R, Gudjonsson J, Tsoi L, Mayes M, Shah A, Kafaja S, Barry W, Goldmuntz E, Smilek D, Khanna D. Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/dose-escalation-safety-study-of-brentuximab-vedotin-for-diffuse-cutaneous-systemic-sclerosisclinical-results-and-mechanistic-analysis-of-skin-and-peripheral-blood-mononuclear-cells/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dose-escalation-safety-study-of-brentuximab-vedotin-for-diffuse-cutaneous-systemic-sclerosisclinical-results-and-mechanistic-analysis-of-skin-and-peripheral-blood-mononuclear-cells/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology